Week Ending June 2, 2021

Biodesix, Addario Lung Cancer Institute Enroll First Patient in NSCLC Biomarker Study
“NEW YORK – The Addario Lung Cancer Medical Institute and Biodesix said on Wednesday that they have enrolled the first non-small cell lung cancer patient in a trial evaluating biomarkers predictive of response to immunotherapy using Biodesix’s Primary Immune Response, or PIR, test.”

Key to Leveraging Emerging Approaches in Lung Cancer Lies in Balancing Benefit With Risk
“Novel immunotherapy combinations are gaining ground in the frontline treatment of patients with lung cancer, but the toxicities associated with these regimens must be weighed against the benefit they provide, according to Michael Shafique, MD. Emerging approaches, such as next-generation antibody-drug conjugates (ADCs), could potentially overcome tolerability challenges and provide an option to those who progress on immunotherapies.”

FDA approves Amgen drug for lung cancer with specific mutation
“The medication is designed to target a gene mutation that occurs in about 13 percent of non-small cell lung cancers. The U.S. Food and Drug Administration on Friday approved an Amgen drug for non-small cell lung cancer with a specific mutation in a gene known as KRAS in patients whose disease has worsened after treatment with chemotherapy or other medicines.”

Large-scale Lung Cancer Clinical Study Demonstrates Accuracy and Sensitivity of Fluxion’s ERASE-Seq Liquid Biopsy
“Fluxion Biosciences announced the publication of a paper on ERASE-Seq™ liquid biopsy with molecular amplification pools (MAPs). The paper, “Sensitivity, specificity, and accuracy of a liquid biopsy approach utilizing molecular amplification pools”, published in Nature Scientific Reports on May 24, is co-authored by researchers at Fluxion and the Hospices Civils de Lyon Cancer Institute. Data showed the ERASE-Seq/MAPs approach to have a 98.8% concordance to the benchmark droplet digital PCR (ddPCR) approaches.”

Don’t Delay Lung Cancer Surgery, Study Suggests
“FRIDAY, May 28, 2021 (HealthDay News) — Surgery soon after a diagnosis of early-stage lung cancer is crucial in reducing the risk of recurrence and death, a new study finds.”

Video:
Immunotherapy for First-Line Extensive-Stage SCLC
“A discussion regarding typical response rates to frontline therapy for extensive-stage small cell lung cancer and considerations for incorporating an immunotherapy agent into first-line treatment.”

Dr. Socinski on the Utility of ctDNA Testing in Lung Cancer
“Mark A. Socinski, MD, executive medical director of the AdventHealth Cancer Institute, discusses the utility of circulating tumor DNA (ctDNA) testing in lung cancer.”